E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα

Cell Cycle

Volumn 13, Issue 8, 2014, Pages 1277-1287

  Zhang, Lei ^a   Zhou, Qian ^a   Zhang, Ning ^b   Li, Weixu ^b   Ying, Meidan ^a   Ding, Wanjing ^a   Yang, Bo ^a   He, Qiaojun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

All trans retinoic acid; ATRA; E2F1; Osteogenic differentiation; Osteosarcoma; RAR

Indexed keywords

RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR E2F1; ANTINEOPLASTIC AGENT; E2F1 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; TUMOR MARKER;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE DEVELOPMENT; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PREDICTIVE VALUE; PRIMARY CULTURE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION; UBIQUITINATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; E2F1 TRANSCRIPTION FACTOR; HUMANS; OSTEOGENESIS; OSTEOSARCOMA; PROTEOLYSIS; RECEPTORS, RETINOIC ACID; TRETINOIN; UBIQUITINATION;

EID: 84899053880     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28190     Document Type: Article

References (50)

1. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995; 75(Suppl):203-10; PMID:8000997; http://dx.doi.org/10.1002/1097-0142(19950101)75:1+<203:: AIDCNCR2820751308>3.0.CO;2-V
2. Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011; 2011:959248; PMID:21559216; http://dx.doi.org/10.1155/2011/959248
3. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005; 65:1748-54; PMID:15753370; http://dx.doi.org/10.1158/0008-5472.CAN-04-2463
4. Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, Bertz J, Jentzsch T, Puskas GJ, Born W, Fuchs B. Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res 2012; 27:58-67; PMID:21976359; http://dx.doi.org/10.1002/jbmr.535
5. Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR, Holloway AJ, et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004; 167:925-34; PMID:15583032; http://dx.doi.org/10.1083/jcb. 200409187
6. Haydon RC, Luu HH, He TC. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 2007; 454:237-46; PMID:17075380; http://dx.doi.org/10.1097/BLO.0b013e31802b683c
7. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PC. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009; 219:294-305; PMID:19718709; http://dx.doi.org/10.1002/ path.2603
8. Dai X, Ma W, He X, Jha RK. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit 2011; 17:RA177-90; PMID:21804475; http://dx.doi.org/10.12659/MSM.881893
9. Degos L, Dombret H, Chomienne C, Daniel MT, Micléa JM, Chastang C, Castaigne S, Fenaux P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85:2643-53; PMID:7742522
10. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003; 197:185-92; PMID:12880980; http://dx.doi.org/10.1016/S0304-3835(03)00108-3
11. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 2006; 13:51-68; PMID:16601279; http://dx.doi.org/10.1677/erc.1.00938
12. Zhang H, Satyamoorthy K, Herlyn M, Rosdahl I. All-trans retinoic acid (atRA) differentially induces apoptosis in matched primary and metastatic melanoma cells - a speculation on damage effect of atRA via mitochondrial dysfunction and cell cycle redistribution. Carcinogenesis 2003; 24:185-91; PMID:12584166; http://dx.doi.org/10.1093/carcin/24.2.185
13. Garattini E, Paroni G, Terao M. Retinoids and breast cancer: new clues to increase their activity and selectivity. Breast Cancer Res 2012; 14:111; PMID:22992337; http://dx.doi.org/10.1186/bcr3245
14. Luo P, Yang X, Ying M, Chaudhry P, Wang A, Shimada H, May WA, Adams GB, Mock D, Triche TJ, et al. Retinoid-suppressed phosphorylation of RARalpha mediates the differentiation pathway of osteosarcoma cells. Oncogene 2010; 29:2772-83; PMID:20190807; http://dx.doi.org/10.1038/onc.2010.50
15. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, Ishikawa A, Peabody T, Montag A, Simon MA, et al. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 2002; 8:1288-94; PMID:12006550
16. Hisada K, Hata K, Ichida F, Matsubara T, Orimo H, Nakano T, Yatani H, Nishimura R, Yoneda T. Retinoic acid regulates commitment of undifferentiated mesenchymal stem cells into osteoblasts and adipocytes. J Bone Miner Metab 2013; 31:53-63; PMID:23014973; http://dx.doi.org/10.1007/s00774-012-0385-x
17. Dingwall M, Marchildon F, Gunanayagam A, Louis CS, Wiper-Bergeron N. Retinoic acid-induced Smad3 expression is required for the induction of osteoblastogenesis of mesenchymal stem cells. Differentiation 2011; 82:57-65; PMID:21612856; http://dx.doi.org/10.1016/j.diff.2011.05.003
18. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell 2007; 131:242-56; PMID:17956727; http://dx.doi.org/10.1016/ j.cell.2007.10.004
19. Fukuda K, Fujita J. Mesenchymal, but not hematopoietic, stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction in mice. Kidney Int 2005; 68:1940-3; PMID:16221170; http://dx.doi.org/10.1111/j. 1523-1755.2005.00624.x
20. Heino TJ, Hentunen TA. Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther 2008; 3:131-45; PMID:18473879; http://dx.doi.org/10.2174/157488808784223032
21. Bell LA, Ryan KM. Life and death decisions by E2F-1. Cell Death Differ 2004; 11:137-42; PMID:14526389; http://dx.doi.org/10.1038/sj.cdd.4401324
22. Wang J, Helin K, Jin P, Nadal-Ginard B. Inhibition of in vitro myogenic differentiation by cellular transcription factor E2F1. Cell Growth Differ 1995; 6:1299-306; PMID:8845307
23. Guy CT, Zhou W, Kaufman S, Robinson MO. E2F-1 blocks terminal differentiation and causes proliferation in transgenic megakaryocytes. Mol Cell Biol 1996; 16:685-93; PMID:8552097
24. Fajas L, Landsberg RL, Huss-Garcia Y, Sardet C, Lees JA, Auwerx J. E2Fs regulate adipocyte differentiation. Dev Cell 2002; 3:39-49; PMID:12110166; http://dx.doi.org/10.1016/S1534-5807(02)00190-9
25. Dani N, Olivero M, Mareschi K, van Duist MM, Miretti S, Cuvertino S, Patané S, Calogero R, Ferracini R, Scotlandi K, et al. The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteoprogenitors. J Bone Miner Res 2012; 27:1322-34; PMID:22367914; http://dx.doi.org/10.1002/jbmr.1578
26. Sodek J, Chen J, Nagata T, Kasugai S, Todescan R Jr., Li IW, Kim RH. Regulation of osteopontin expression in osteoblasts. Ann N Y Acad Sci 1995; 760:223-41; PMID:7785896; http://dx.doi.org/10.1111/j.1749-6632.1995.tb44633.x
27. Liu PP, Leung KS, Kumta SM, Lee KM, Fung KP. Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. Oncology 1996; 53:275-80; PMID:8692530; http://dx.doi.org/10.1159/000227573
28. Zhu J, Gianni M, Kopf E, Honoré N, Chelbi-Alix M, Koken M, Quignon F, Rochette-Egly C, de Thé H. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A 1999; 96:14807-12; PMID:10611294; http://dx.doi.org/10.1073/pnas.96.26.14807
29. Fang Y, Zhou X, Lin M, Ying M, Luo P, Zhu D, Lou J, Yang B, He Q. Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Mol Carcinog 2011; 50:24-35; PMID:20945414; http://dx.doi.org/10.1002/mc.20687
30. Laue K, Jänicke M, Plaster N, Sonntag C, Hammerschmidt M. Restriction of retinoic acid activity by Cyp26b1 is required for proper timing and patterning of osteogenesis during zebrafish development. Development 2008; 135:3775-87; PMID:18927157; http://dx.doi.org/10.1242/dev.021238
31. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-93; PMID:11902573; http://dx.doi.org/10.1038/ 35106036
32. Kelly WK, Osman I, Reuter VE, Curley T, Heston WD, Nanus DM, Scher HI. The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin Cancer Res 2000; 6:838-46; PMID:10741705
33. Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res 2013; 19:1651-9; PMID:23322901; http://dx.doi.org/10. 1158/1078-0432.CCR-12-3175
34. Ferrari N, Morini M, Pfeffer U, Minghelli S, Noonan DM, Albini A. Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clin Cancer Res 2003; 9:6020-9; PMID:14676128
35. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10:839-64; PMID:1569455
36. Verhaegen M, Checinska A, Riblett MB, Wang S, Soengas MS. E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene 2012; 31:828-41; PMID:21743494; http://dx.doi.org/10.1038/onc.2011.277
37. Pützer BM. E2F1 death pathways as targets for cancer therapy. J Cell Mol Med 2007; 11:239-51; PMID:17488475; http://dx.doi.org/10.1111/j.1582-4934. 2007.00030.x
38. Diao H, Li X, Hu S, Liu Y. Gene expression profiling combined with bioinformatics analysis identify biomarkers for Parkinson disease. PLoS One 2012; 7:e52319; PMID:23284986; http://dx.doi.org/10.1371/journal.pone.0052319
39. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002; 198:142-56; PMID:12237873; http://dx.doi.org/10.1002/path.1121
40. Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, Flury R, Dieterich H, Spyratos F, Eppenberger U, et al. Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res 2007; 9:R33; PMID:17535433; http://dx.doi.org/10.1186/bcr1681
41. Gianni M, Peviani M, Bruck N, Rambaldi A, Borleri G, Terao M, Kurosaki M, Paroni G, Rochette-Egly C, Garattini E. p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells. Leukemia 2012; 26:1850-61; PMID:22354283; http://dx.doi.org/10.1038/leu.2012.50
42. Ozaki T, Okoshi R, Ono S, Kubo N, Nakagawara A. Deregulated expression of E2F1 promotes proteolytic degradation of tumor suppressor p73 and inhibits its transcriptional activity. Biochem Biophys Res Commun 2009; 387:143-8; PMID:19576172; http://dx.doi.org/10.1016/j.bbrc.2009.06.141
43. Itoshima T, Fujiwara T, Waku T, Shao J, Kataoka M, Yarbrough WG, Liu TJ, Roth JA, Tanaka N, Kodama M. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin Cancer Res 2000; 6:2851-9; PMID:10914734
44. Strachan GD, Rallapalli R, Pucci B, Lafond TP, Hall DJ. A transcriptionally inactive E2F-1 targets the MDM family of proteins for proteolytic degradation. J Biol Chem 2001; 276:45677-85; PMID:11568180; http://dx.doi.org/10.1074/jbc.M103765200
45. Ying M, Zhou X, Zhong L, Lin N, Jing H, Luo P, Yang X, Song H, Yang B, He Q. Bortezomib sensitizes human acute myeloid leukemia cells to all-transretinoic acid-induced differentiation by modifying the RARα/STAT1 axis. Mol Cancer Ther 2013; 12:195-206; PMID:23243061; http://dx.doi.org/10. 1158/1535-7163.MCT-12-0433
46. Cao J, Xu D, Wang D, Wu R, Zhang L, Zhu H, He Q, Yang B. ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med 2009; 47:536-47; PMID:19482076; http://dx.doi.org/10. 1016/j.freeradbiomed.2009.05.024
47. Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, Katzenellenbogen BS. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 2007; 21:2112-23; PMID:17550982; http://dx.doi.org/10.1210/me.2006-0474
48. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007; 67:2089-97; PMID:17332338; http://dx.doi.org/10.1158/0008-5472.CAN- 06-3625
49. Paik JC, Wang B, Liu K, Lue JK, Lin WC. Regulation of E2F1-induced apoptosis by the nucleolar protein RRP1B. J Biol Chem 2010; 285:6348-63; PMID:20040599; http://dx.doi.org/10.1074/jbc.M109.072074
50. Kadowaki S, Chikumi H, Yamamoto H, Yoneda K, Yamasaki A, Sato K, Shimizu E. Down-regulation of inducible nitric oxide synthase by lysophosphatidic acid in human respiratory epithelial cells. Mol Cell Biochem 2004; 262:51-9; PMID:15532709; http:// dx.doi.org/10.1023/B:MCBI.0000038215.89821.7f